Time filter

Source Type

Rauth S.,Chittaranjan National Cancer Institute | Ray S.,Chittaranjan National Cancer Institute | Bhattacharyya S.,Chittaranjan National Cancer Institute | Mehrotra D.G.,Mitra Biotech | And 6 more authors.
Molecular and Cellular Biochemistry | Year: 2016

Epidermal growth factor receptor (EGFR) pathway is overexpressed in head and neck cancer (HNC). Lupeol, a natural triterpene (phytosterol found in fruits, vegetables, etc.), has been reported to be effective against multiple cancer indications. Here we investigate the antitumor effects of Lupeol and underlying mechanism in oral cancer. Lupeol-induced antitumor response was evaluated in two oral squamous cell carcinoma (OSCC) cell lines (UPCI:SCC131 and UPCI:SCC084) by viability (MTT), proliferation, and colony formation assays. Lupeol-mediated induction of apoptosis was examined by caspase 3/7 assay and flow cytometry. Effect of Lupeol on EGFR in the presence or absence of EGF was delineated by Western blot. The mRNA stability assay was performed to check the role of Lupeol on COX-2 mRNA regulation. Lupeol inhibited proliferation of OSCC cells in vitro by inducing apoptosis 48 h post treatment. Ligand-induced phosphorylation of EGFR and subsequent activation of its downstream molecules such as protein kinase B (PKB or AKT), I kappa B (IκB), and nuclear factor kappa B (NF-κB) was also found to be, in part, suppressed. Interestingly, Lupeol suppressed expression of COX-2 at mRNA and protein level in a time-dependent manner. Primary explants from oral squamous cell carcinoma tissues further confirmed significant inhibition of proliferation (Ki67) in Lupeol-treated explants as compared to untreated control at 48 h. Together these data suggest that Lupeol may act as a potent inhibitor of the EGFR signaling in OSCC and therefore imply its role in triggering antitumor efficacy. © 2016, Springer Science+Business Media New York. Source

Mitra Biotech | Entity website

Company Mitra Biotech is a pioneer is enabling personalized cancer care and drug development

Mitra Biotech | Entity website

India 202, Narayana Nethralaya Narayana Health City Hosur Main Road, Bommasandra Bangalore, Karnataka 560099 +91 80 6666 0750

The present disclosure relates to an Extra Cellular Matrix composition specific for cancer type and a tumor microenvironment platform for long term culturing of tumor tissue, wherein said culturing provides human ligands and tumor tissue micro-environment to mimic physiologically relevant signalling systems. The present disclosure further relates to the development of a Clinical Response Predictor and its application in the prognostic field (selection of treatment option for the patient) and translational biology field (development of anticancer drugs). The disclosure further relates to a method of predicting clinical response of a tumor patient to drug(s). The disclosure further relates to a method for screening tumor cells for the presence of specific markers for determining the viability of said cells for indication of tumor status.

News Article | October 25, 2013
Site: yourstory.com

Financial advisory firm Masterkey Holdings today announced the closure of the Series B Fund raise for Mitra Biotech from Tata Capital Innovations Fund. Mitra Biotech Pvt Ltd is a transnational Biology company focused on “Patient Segregation” in the area of cancer research. Mitra Biotech has developed a novel technology for the creation of local microenvironment mirroring tumor microenvironment for different cancers. They have developed diagnostic tests for targeted drugs, chemotherapeutics and for auto-immune diseases and inflammatory disorders. Founded by a team of medical researchers from the Massachusetts Institute of Technology and Harvard Medical School, and with R&D centre in Bangalore and labs at Boston, Mitra Biotech works with some of the country’s top oncology institutes to determine the optimal drug or combination of drugs for patients. This helps reduce the overall treatment cycle and toxicity of conventional cancer medicines. Mitra Biotech first raised venture funding form Accel partners, India Innovation Fund and Kitven, for the development of Oncoprint their IP-based product with applications in Translational Biology and Theranostics. The latest round of funding will be used to scale operations, expand globally and strengthen the business development and research teams.

Discover hidden collaborations